open access

Vol 15, No 6 (2008)
Original articles
Published online: 2008-09-22
Submitted: 2013-01-14
Get Citation

Natriuretic peptides in patients with atrial fibrillation

Beata Wożakowska-Kapłon, Grzegorz Opolski, Zbigniew Herman, Dariusz Kosior
Cardiol J 2008;15(6):525-529.

open access

Vol 15, No 6 (2008)
Original articles
Published online: 2008-09-22
Submitted: 2013-01-14

Abstract


Background: The aim of the study was to evaluate plasma natriuretic peptides (NPs): atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) concentrations in patients with paroxysmal, persistent and permanent atrial fibrillation (AF).
Methods and results: The study groups consisted of 23 patients with paroxysmal AF, 42 patients with permanent AF and 77 patients with persistent AF with normal left ventricular function. The mean ANP level was increased in AF patients in the paroxysmal, persistent and permanent groups: 249 ± 88.3 pg/mL; 258 ± 89.7 pg/mL; 208 ± 76.7 pg/mL, respectively, vs. 67 ± 21.2 pg/mL in the control subjects (p < 0.001). The mean BNP level was increased in AF patients in the paroxysmal, persistent and permanent groups: 99.6 ± 29.8 pg/mL; 82.3 ± 33 pg/mL; 95.6 ± 46.4 pg/mL, respectively, vs. 37.5 ± 13 pg/mL in the control group. Multivariate logistic regression analysis revealed a positive correlation between ANP levels, maximal left atrial volume, heart rate and New York Heart Association (NYHA) classification, in the persistent AF patients. A positive correlation between plasma BNP levels and heart failure stage according to NYHA classification in this group was found. Baseline ANP concentrations were positively correlated with baseline BNP concentrations in AF patients.
Conclusions: Plasma NPs levels are increased in patients with paroxysmal, persistent and permanent AF and normal left ventricle function, and positively correlated with left atrial volume, heart rate and heart failure stage according to NYHA classification. Neurohormonal assessment does not distinguish the type of arrhythmia.

Abstract


Background: The aim of the study was to evaluate plasma natriuretic peptides (NPs): atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) concentrations in patients with paroxysmal, persistent and permanent atrial fibrillation (AF).
Methods and results: The study groups consisted of 23 patients with paroxysmal AF, 42 patients with permanent AF and 77 patients with persistent AF with normal left ventricular function. The mean ANP level was increased in AF patients in the paroxysmal, persistent and permanent groups: 249 ± 88.3 pg/mL; 258 ± 89.7 pg/mL; 208 ± 76.7 pg/mL, respectively, vs. 67 ± 21.2 pg/mL in the control subjects (p < 0.001). The mean BNP level was increased in AF patients in the paroxysmal, persistent and permanent groups: 99.6 ± 29.8 pg/mL; 82.3 ± 33 pg/mL; 95.6 ± 46.4 pg/mL, respectively, vs. 37.5 ± 13 pg/mL in the control group. Multivariate logistic regression analysis revealed a positive correlation between ANP levels, maximal left atrial volume, heart rate and New York Heart Association (NYHA) classification, in the persistent AF patients. A positive correlation between plasma BNP levels and heart failure stage according to NYHA classification in this group was found. Baseline ANP concentrations were positively correlated with baseline BNP concentrations in AF patients.
Conclusions: Plasma NPs levels are increased in patients with paroxysmal, persistent and permanent AF and normal left ventricle function, and positively correlated with left atrial volume, heart rate and heart failure stage according to NYHA classification. Neurohormonal assessment does not distinguish the type of arrhythmia.
Get Citation

Keywords

atrial fibrillation; natriuretic peptides

About this article
Title

Natriuretic peptides in patients with atrial fibrillation

Journal

Cardiology Journal

Issue

Vol 15, No 6 (2008)

Pages

525-529

Published online

2008-09-22

Bibliographic record

Cardiol J 2008;15(6):525-529.

Keywords

atrial fibrillation
natriuretic peptides

Authors

Beata Wożakowska-Kapłon
Grzegorz Opolski
Zbigniew Herman
Dariusz Kosior

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl